Efficacy and Safety of Camrelizumab Combination Therapy in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis.
Umar Akram, Zain A Nadeem, Obaid Ur Rehman et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and random-effects meta-analysis assessed efficacy and safety of camrelizumab combination therapy in women with triple-negative breast cancer. Nine studies involving 357 patients were pooled. The overall response rate was 58% (95% CI: 30%-84%; I2 =94%), while the 1-year survival rate was 71% (95% CI: 54%-85%; I2 =49%). The 1-year progression-free survival rate was 22% (95% CI: 0%-25%; I2 =93%). Neutropenia was the most frequently reported treatment-related adverse event, affecting 66% of patients. The authors describe the findings as promising but note that future phase III trials are needed.
Key findings
- Pooled overall response rate was 58% (95% CI: 30%-84%; I2 =94%).
- The 1-year survival rate was 71% (95% CI: 54%-85%; I2 =49%).
- The 1-year progression-free survival rate was 22% (95% CI: 0%-25%; I2 =93%).
- Neutropenia was reported in 66% of patients; leukopenia in 59%.
Why it matters
The pooled results provide an overview of reported tumour response, survival, and adverse events with camrelizumab combinations in TNBC, where the treatment’s role remains unclear. The high heterogeneity in several outcomes means estimates vary substantially across studies, so these findings are informative for interpreting the evidence base but do not establish a consistent treatment effect.
What to keep in mind
The meta-analysis pooled only nine studies and 357 patients; heterogeneity was high for overall response, 1-year progression-free survival, and several disease-status outcomes.